As contemporary surgical practice continues to evolve, patients who undergo surgical lung volume reduction (LVRS) for ...

If these trials confirm the findings, benralizumab could become the first new therapy approved for eosinophilic exacerbations ...

After waking up from the procedure, he told me he could take full breaths for the first time in years,” Dr. Mark Sigler said ...

Here, Tan and other experts in the field describe how this new understanding of inflammation is informing treatment. And it's ...

we can inspire innovative and expedited therapeutic solutions for COPD,” Dr. Hamilton said. “This will give us the opportunity to maximize the treatment benefit of new therapies for patients.” ...

UK pharma major AstraZeneca’s Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 ...

There is no evidence that Oz or Snoop Dogg has ever developed or advertised any over-the-counter COPD treatment. David Mannino, chief medical officer and co-founder of the COPD Foundation ...

AstraZeneca’s new inhaler Bevespi Aerosphere (glycopyrronium/formoterol fumarate) has been approved in Europe, as a maintenance treatment for chronic obstructive ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...

For decades, the standard treatment for these potentially ... benralizumab could become the first new therapy approved for eosinophilic exacerbations of asthma and COPD in over 50 years.

For many in the Texas Panhandle, a groundbreaking procedure is offering a new lease on life ... is a minimally invasive treatment for severe or very severe COPD and emphysema.